GeneNews Limited focuses on developing and commercializing proprietary molecular diagnostic tests for the early detection of diseases and personalized health management with a primary focus on cancer-related indications. Its proprietary platform technology, the Sentinel Principle, identifies novel biomarkers from whole blood. The company's lead product is ColonSentry, a blood test to determine an individual's current risk for having colorectal cancer. GeneNews Limited was founded in 1998 and is headquartered in Richmond Hill, Canada.
Industry, Sector and Symbol
Industry Diagnostics & Research
Sub-IndustryN/A
SectorMedical
CIKN/A
Phone+1-905-7392030
Debt
Price-To-Earnings
Sales & Book Value
Annual SalesC$234,592.00
Profitability
Miscellaneous
Employees15
Next Earnings DateN/A
OptionableOptionable
GeneNews (TSE:GEN) Frequently Asked Questions
What is GeneNews' stock symbol?
GeneNews trades on the Toronto Stock Exchange (TSX) under the ticker symbol "GEN."
Has GeneNews been receiving favorable news coverage?
Media stories about GEN stock have been trending very negative recently, according to InfoTrie Sentiment. The research group ranks the sentiment of news coverage by analyzing more than six thousand blog and news sources in real time. The firm ranks coverage of public companies on a scale of -5 to 5, with scores closest to five being the most favorable. GeneNews earned a news impact score of -3.2 on InfoTrie's scale. They also gave press coverage about the company a news buzz of 0.0 out of 10, indicating that recent news coverage is extremely unlikely to have an impact on the stock's share price in the near term. View News Stories for GeneNews.
Who are some of GeneNews' key competitors?
Some companies that are related to GeneNews include Yourgene Health (YGEN), MaxCyte (MXCT), BARD1 Life Sciences (BD1), Oncosil Medical (OSL), Oncimmune (ONC), Sernova (SVA), Lexagene (LXG), SQI Diagnostics (SQD), Deepmatter Group (DMTR), Imagion Biosys (IBX), LED Medical Diagnostics (LMD), Dorsavi (DVL), VentriPoint Diagnostics (VPT), Cambridge Cognition (COG) and Genedrive (GDR).
What other stocks do shareholders of GeneNews own?
Who are GeneNews' key executives?
GeneNews' management team includes the folowing people:
- Mr. James R. Howard-Tripp, Exec. Chairman & CEO
- Ms. Joanna M. Halsey Esq., Gen. Counsel, Chief Compliance Officer & HR Director of IDL
- Prof. Choong-Chin Liew Ph.D., Co-Founder
- Mr. Warren Whitehead, Chief Accountant (Age 67)
- Mr. David Suria, Sr. Scientist
How do I buy shares of GeneNews?
Shares of GEN and other Canadian stocks can be purchased through online brokerage accounts that support trading on the Toronto Stock Exchange (TSX). Brokers that permit trading on the TSX include Fidelity, Interactive Brokers, PennTrade and Charles Schwab.
How big of a company is GeneNews?
What is GeneNews' official website?
How can I contact GeneNews?
GeneNews' mailing address is 445 Apple Creek Blvd Unit 220, MARKHAM, ON L3R 9X7, Canada. The company can be reached via phone at +1-905-7392030.
MarketBeat Community Rating for GeneNews (TSE GEN)
MarketBeat's community ratings are surveys of what our community members think about GeneNews and other stocks. Vote "Outperform" if you believe GEN will outperform the S&P 500 over the long term. Vote "Underperform" if you believe GEN will underperform the S&P 500 over the long term. You may vote once every thirty days.
